Article
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia.
Science (New York, N.Y.) - 31 Jan 2020
Uckelmann Hannah J, Kim Stephanie M, Wong Eric M, Hatton Charles, Giovinazzo Hugh, Gadrey Jayant Y, Krivtsov Andrei V, Rücker Frank G, Döhner Konstanze, McGeehan Gerard M, Levine Ross L, Bullinger Lars, Vassiliou George S, Armstrong Scott A
Abstract excerpt
The initiating mutations that contribute to cancer development are sometimes present in premalignant cells. Whether therapies targeting these mutations can eradicate premalignant cells is unclear. Acute myeloid leukemia (AML) is an attractive system for investigating the effect of preventative treatment because this disease is often preceded by a premalignant state (clonal hematopoiesis or myelodysplastic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.